Effectiveness of Biologic Therapy in Hidradenitis Suppurativa: Real-World Clinical Outcomes and Lipid Profile...

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with systemic implications. While biologic therapies have demonstrated efficacy in controlling cutaneous lesions, their systemic effects, particularly on lipid metabolism as a marker of systemic inflammation, are less understood.

To evaluate the impact of biologic therapy on clinical severity and lipid profiles in HS patients in a real-world setting, comparing outcomes between Early and Late Responders at Week 24 ± 4.

Twenty-four patients with moderate-to-severe HS on biologic therapy were monitored prospectively at Baseline, Week 24 ± 4, Week 52 and Week 104. Clinical parameters (IHS4, A/N, HS-IGA) and lipid profiles (cholesterol, triglycerides) were analysed. Patients were categorised as Early (IHS4 ≤ 10) or Late Responders (IHS4 ≥ 11) at Week 24 ± 4. Statistical analysis included t-tests; significance was set at p < 0.05.

Early Responders showed significant clinical improvement and reductions in lipid levels, suggesting a systemic anti-inflammatory effect of therapy. However, lipid reductions did not reach statistical significance (p > 0.05); likely due to the small sample size. Late Responders demonstrated less pronounced changes.

Biologic therapy appears to improve both clinical and systemic inflammatory markers in HS, highlighting the value of metabolic monitoring in routine care.